Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MV NIS

Next Previous
X
Search
Drug Profile

MV NIS

Alternative Names: MV-NIS; Sodium Iodide Simporter Measles Virus

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vyriad
  • Developer Mayo Clinic; National Cancer Institute (USA); University of Arkansas System; Vyriad
  • Class Antineoplastics; Cancer vaccines; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Breast cancer; Medulloblastoma; Rhabdoid tumour; Squamous cell cancer; Urethral cancer
  • Discontinued Glioblastoma; Haematological malignancies; Head and neck cancer; Malignant-mesothelioma; Multiple myeloma; Non-small cell lung cancer

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease) in USA (Intratumoural, Injection)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Medulloblastoma(In adolescents, In children, In infants, Recurrent, Second-line therapy or greater, In adults) in USA (Intratumoural)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Rhabdoid-tumour(In adolescents, In children, In infants, Recurrent, Second-line therapy or greater, In adults) in USA (Intratumoural)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top